PRGO — PERRIGO Co plc

NYSE · Health Care · Pharmaceuticals · CIK 1585364 ·
Last close
$10.80
Market Cap
$1.49B
52W High
$13.98
52W Low
$9.23
ADV30
2,300,156
Next earnings
2026-07-31
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Dec 2025 1,109,600,000 362,200,000 84,400,000 -1,418,100,000 8,535,200,000 531,600,000 5,599,700,000
Sep 2025 1,043,300,000 377,100,000 93,400,000 7,500,000 10,084,000,000 432,100,000 5,637,500,000
Jun 2025 1,056,300,000 362,900,000 55,600,000 -8,400,000 10,094,100,000 454,200,000 5,621,800,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$238,500,000
Investing CF
$-75,400,000
Financing CF
$-220,500,000
CapEx
$-93,400,000
Dividends Paid
$-159,300,000
Buybacks
EPS Diluted TTM
$-13.10
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-3,677,500,000
Inventory
$1,149,000,000
Receivables
$612,800,000
ST Investments
EBIT TTM
$-1,135,300,000
Pretax Income TTM
$-1,297,800,000
Interest Exp TTM
$162,500,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,178,400,000
EBITDA
$637,299,968
Free Cash Flow
$108,425,000
Enterprise Value
$5,023,986,176
Total Cash
$357,200,000
Total Debt
$3,828,699,904
Shares Out
138,367,770
Trailing EPS
$-12.93
Book Value
$21.33
ROE
-52.2%
ROA
2.1%
Div Yield
10.34%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 4,253,100,000 312,800,000 -1,425,400,000 8,535,200,000 5,599,700,000 238,500,000
Dec 2024 4,373,400,000 311,900,000 -171,800,000 9,647,700,000 5,328,300,000 362,900,000
Dec 2023 4,655,600,000 284,100,000 -12,700,000 10,809,100,000 6,041,200,000 405,500,000
Dec 2022 4,451,600,000 121,400,000 -140,600,000 11,017,300,000 6,175,200,000 307,300,000

TTM Snapshot

Revenues TTM
$4,354,200,000
NetIncome TTM
$-115,100,000
OpCashFlow TTM
$0
Assets (Latest)
$9,647,700,000
Forward EPS
$2.36

Peers — same industry

TickerNameMarket CapLastDaily %
SLS SELLAS Life Sciences Group, Inc. $1.51B $8.12
MBX MBX Biosciences, Inc. $1.51B $31.75
PGEN PRECIGEN, INC. $1.51B $4.24
BHVN Biohaven Ltd. $1.52B $10.07
AMLX Amylyx Pharmaceuticals, Inc. $1.52B $13.68

News headlines (Yahoo Finance, 1h cache)

Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
2026-05-26 12:30 · Yahoo
Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y
2026-05-07 16:56 · Yahoo
Assessing Perrigo (PRGO) Valuation After Weak Q1 Results And Lowered Guidance
2026-05-07 14:21 · Yahoo
Perrigo Company plc Q1 2026 Earnings Call Summary
2026-05-07 12:30 · Yahoo
Perrigo (PRGO) Q1 Earnings Beat Estimates
2026-05-06 11:45 · Yahoo
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
2026-05-06 10:30 · Yahoo
How Investors Are Reacting To Perrigo (PRGO) Dermacosmetics Sale, Dividend Payout, And Infant Formula Strains
2026-05-05 23:24 · Yahoo
Perrigo Completes Divestiture of Dermacosmetics Business
2026-04-30 20:30 · Yahoo
ICU Medical (ICUI) Reports Next Week: Wall Street Expects Earnings Growth
2026-04-30 14:00 · Yahoo
Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for
2026-04-29 14:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.